Suppression of the Neoplastic Phenotype in Vivo by an Anti-ras Ribozyme

Cancer Research

Volumn 54, Issue 4, 1994, Pages 900-902

  Kashani Sabet, Mohammed ^a   Funato, Tadao ^b   Florenes, Vivi Ann ^c   Fodstad, Oystein ^c   Scanlon, Kevin J ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RIBOZYME; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL STRAIN 3T3; COLONY FORMATION; CONTROLLED STUDY; DNA SYNTHESIS; DNA TRANSFECTION; GENE THERAPY; HUMAN; HUMAN CELL; MELANOMA CELL; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUDE MOUSE; ONCOGENE H RAS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

3T3 CELLS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE THERAPY; GENES, RAS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PHENOTYPE; RNA, CATALYTIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0028347648     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Haseloff, J., and Gerlach, W. L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (Lond.), 334: 585-591, 1988.
2. Sarver, N., Cantin, E. M., Chang, P. S., Zaia, J. A., Ladne, P. A., Stephens, D. A., and Rossi, J. J. Ribozymes as potential anti-HIV-1 therapeutic agents. Science (Washington DC), 247: 1222-1225, 1990.
3. Scanlon, K. J., Jiao, L., Funato, T., Wang, W., Tone, T. J., Rossi, J., and Kashani-Sabet, M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl. Acad. Sci. USA, 88: 10591- 10595, 1991.
4. Kashani-Sabet, M., Funato, T., Tone, T., Jiao, L., Wang, W., Yoshida, E., Kashfinn, B. I., Shitara, T., Wu, A. M., Moreno, J. G., Traweek, S. T., Ahlering, T. E., and Scanlon, K. J. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res. & Dev., 2: 3-15, 1992.
5. Barbacid, M. ras genes. Annu. Rev. Biochem., 56: 779-827, 1987.
6. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
7. Ohta, Y., Tone, T., Shitara, T., Funato, T., Jiao, L., Kashfian, B. I., Yoshida, E., Horng, M., Tsai, P., Lauterbach, K., Kashani-Sabet, M., and Scanlon, K. J. H-ras ribozyme-mediated alteration of the human melanoma phenotype. Ann. NY Acad. Sci., in press, 1993.
8. Funato, T., Yoshida, E., Jiao, L., Tone, T., Kashani-Sabet, M., and Scanlon, K. J. The utility of an antifos ribozyme in reversing cisplatin resistance in human carcinomas. Advan. Enzyme Regul., 32: 195-209, 1992.
9. Kjonniksen, I., Hoifodt, H. K., Pihl, A., and Fodstad, O. Different metastasis patterns of a human melanoma cell line in nude mice and rats: influence of microenvironment. J. Natl. Cancer Inst., 83: 1020-1024, 1991.
10. Fodstad O. Transplantability of human tumors. In: E. Boven and B. Winograd (eds.), Nude Mice in Oncology Research, pp. 66-76. Boca Raton, FL: CRC Press, 1991.
11. Huang, H. J. S., Yee, J. K., Shew, J. Y., Chen, P. L., Bookstein, R., Friedmann, T., Lee, E. Y-H. P., and Lee, W. H. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science (Washington DC), 242: 1563-1566, 1988.
12. Chen, P. L., Chen, Y., Bookstein, R., and Lee, W. H. Genetic mechanisms of tumor suppression by the human p53 gene. Science (Washington DC), 250: 1576-1580, 1990.
13. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
14. Postel, E. H., Flint, S. J., Kessler, D. J., and Hogan, M. E. Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc. Natl. Acad. Sci. USA, 88: 8227-8231, 1991.
15. Neckers, L., Whitesell, L., Rosolen, A., and Geselowitz, D. A. Antisense inhibition of oncogene expression. Crit. Rev. Oncogenesis, 3: 175-231, 1992.
16. Ratajczak, M. Z., Kant, J. A., Luger, S. M., Hijiya, N., Zhang, J., Zon, G., and Gewirtz, A. M. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA, 89: 11823-11827, 1992.
17. Saison-Behmoaras, T., Tocque, B., Rey, I., Chassignol, M., Thuong, N. T., and Helene, C. Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J., 10: 1111-1118, 1991.
18. Chang, E. H., Miller, P. S., Cushman, C., Devadas, K., Pirollo, K. F., Ts'o, P. O. P., and Yu, ZP. Antisense inhibition of ras p. 1 expression that is sensitive to a point mutation. Biochemistry, 30: 8283-8286, 1991.
19. Monia, B. P., Johnston, J. F., Ecker, D. J., Zounes, M. A., Lima, W. F., and Freier, S. M. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem., 267: 19954-19962, 1992.
20. Mukhopadhyay, T., Tainsky, M., Cavender, A. C., and Roth, J. A. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res., 51: 1744-1748, 1991.
21. Simons, M., Edelman, E. R., DeKeyser, J. L., Langer, R., and Rosenberg, R. D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (Lond.), 359: 67-70, 1992.
22. Cech, T. R. Ribozymes and their medical implications. JAMA, 260: 3030-3034, 1988.
23. Koizumi, M., Kamiya, H., and Ohtsuka, E. Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene. Gene, 777: 179-184, 1992.